LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Non-Toxic Drug Combination Induces Stress that Kills Cancer Cells

By LabMedica International staff writers
Posted on 31 May 2016
Print article
Image: Combining 2-DG with fenofibrate yields two forms of cancer cell death (Photo courtesy of the University of Miami School of Medicine).
Image: Combining 2-DG with fenofibrate yields two forms of cancer cell death (Photo courtesy of the University of Miami School of Medicine).
Growth of several different types of cancers was blocked by combined treatment with the sugar 2-Deoxy-D-glucose (2-DG) and the cholesterol-lowering drug fenofibrate.

The sugar 2-DG is a glucose molecule that has the two-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. Fenofibrate is a drug of the fibrate class that is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels. It is used alone or with statins in the treatment of hypercholesterolemia and hypertriglyceridemia.

Unregulated growth and replication as well as an abnormal microenvironment, leads to elevated levels of stress, which is a common trait of cancer. By inducing both energy and endoplasmic reticulum (ER) stress, 2-DG is particularly well suited to take advantage of the therapeutic window that heightened stress in tumors provides. Under hypoxia, blocking glycolysis with 2-DG leads to significant lowering of ATP, which results in energy stress and cell death in numerous carcinoma cell types. In contrast, at normal levels of oxygen, 2-DG at a low-concentration is not toxic in most carcinomas tested, but induces growth inhibition, which is primarily due to ER stress.

Investigators at the University of Miami School of Medicine (FL, USA) reported in the May 10, 2016, online edition of the journal Oncotarget that they had identified a synergistic toxic effect in several tumor cell lines in vitro by combining 2-DG with fenofibrate. This combination induced much greater energy stress than either agent alone, as measured by ATP reduction, increased p-AMPK, and downregulation of mTOR.

Mammalian target of rapamycin (mTOR) is a master regulator of protein synthesis that under ordinary conditions induces cells to grow and divide. In situations of severe nutrient deprivation mTOR prevents protein synthesis so that the cell can conserve energy. However, in cancer cells the mTOR pathway does not function correctly and signals tumor cells to grow, divide, undergo metastasis, and invade new, healthy tissues.

Inhibition of mTOR resulted in blockage of GRP78 (Binding immunoglobulin protein), a critical component of the unfolded protein response. This probably led to greater ER stress.

"We believe our findings effectively pave the way for using this combination to provide non-toxic treatments for a wide variety of cancers," said senior author Dr. Theodore Lampidis, professor of cell biology at the University of Miami School of Medicine. "We found that the unique combination of 2-DG and fenofibrate simultaneously provoked two types of stress, known as energy and ER stress, which most cancer types cannot overcome."

"Cancer cells found in the inner core of all solid tumors - due to the abnormally low levels of oxygen they are in - must rely on the process of glycolysis, the breakdown of glucose for energy, to survive," said Dr. Lampidis. "These cells, by nature of their slow growth, have been found to be the most resistant to conventional cancer treatments such as radiation and chemotherapy. In this study, we showed that a false sugar such as 2-DG, which blocks glycolysis, selectively starves these slow-growing cancer cells while sparing normal cells, which can use other sources of energy, such as fats and proteins because they are fully oxygenated."

Related Links:
University of Miami School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more